בליאומיצין PFI

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

BLEOMYCIN SULFATE

Pieejams no:

MEGAPHARM LTD

ATĶ kods:

L01DC01

Zāļu forma:

אבקה להכנת תמיסה לזריקה

Kompozīcija:

BLEOMYCIN SULFATE 15000 IU/VIAL

Ievadīšanas:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Receptes veids:

מרשם נדרש

Ražojis:

BAXTER ONCOLOGY GmbH, GERMANY

Ārstniecības grupa:

BLEOMYCIN

Ārstniecības joma:

BLEOMYCIN

Ārstēšanas norādes:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Autorizācija datums:

2020-09-30